What is SkyCell?
Founded in 2012 and headquartered in Zug, Switzerland, SkyCell specializes in the development and manufacturing of advanced medical containers designed to maintain the integrity of pharmaceutical products during transit. The company's innovative solutions address the critical need for reliable cold chain logistics within the life sciences sector. SkyCell's technology is crucial for preventing spoilage and ensuring the efficacy of sensitive medications, positioning it as a key player in the global pharmaceutical supply chain.
How much funding has SkyCell raised?
SkyCell has raised a total of $269.8M across 4 funding rounds:
Other Financing Round
$62M
Series C
$34.8M
Other Financing Round
$57M
Series D
$116M
Other Financing Round (2020): $62M with participation from Swiss Entrepreneurs Fund, MVM Partners, and BCGE Bank
Series C (2021): $34.8M, investors not publicly disclosed
Other Financing Round (2023): $57M supported by Catalyst
Series D (2024): $116M featuring Catalyst Investors, Tybourne Capital Management, and Commonwealth Cyber Initiative
Key Investors in SkyCell
Catalyst Investors
Catalyst Investors is a growth equity firm located in New York that specializes in actively helping B2B companies scale their operations and achieve their full potential. With over 20 years of experience, they provide strategic, tactical, and financial support to entrepreneurs during critical growth phases.
Tybourne Capital Management
Tybourne Capital Management is an investment advisory firm that offers a variety of investment relates services to clients.
Commonwealth Cyber Initiative
The Commonwealth Cyber Initiative (CCI) serves as Virginia's primary hub for cybersecurity research, innovation, and workforce development. It connects researchers with funding and collaboration opportunities while helping students explore diverse career paths in cybersecurity.
What's next for SkyCell?
The recent major strategic investment signals a new phase of expansion and development for SkyCell. This capital infusion is expected to fuel further innovation in their container technology, enhance manufacturing capabilities, and broaden their market reach. The company is likely to focus on scaling its operations to meet the growing global demand for secure pharmaceutical logistics, potentially exploring new partnerships and expanding its service offerings to cater to a wider range of medical and biotech clients. This strategic financing will be instrumental in solidifying SkyCell's position as a leader in the specialized field of medical cold chain solutions.
See full SkyCell company page
